MedElevator Войти в исследования
← Поиск публикаций

DOI 10.21037/tlcr-2025-708

Медицинская библиотека · Translational lung cancer research · 2025

Single-cell RNA profiling reveals an immunosuppressive microenvironment in EGFR double-mutant non-small cell lung cancer.

Yang Jiao, Su Jun-Wei, Li Hong-Rui, Fang Mei-Mei, Guan Xu-Hui, Lin Xiao-Cheng, Liu Ke-Jun, Yan Li-Xu, Zhang Xu-Chao, Yang Xue-Ning, Zhong Wen-Zhao, Chen Hua-Jun, Liu Jia, Wu Wendy, Yang Jin-Ji

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Non-small cell lung cancer (NSCLC) patients with double-driver gene mutations are reported with poorer survival outcomes and reduced therapy responses compared to single-mutant (SM) patients. While substantial progress has been made in treating cancers with single-driver gene alterations, the therapeutic implications and tumor microenvironment of double-mutant (DM) NSCLC remain largely unexplored because of its rarity and poor prognosis. This study aims to delineate the landscape of the immune microenvironment within DM NSCLC.

METHODS

We employed single-cell RNA sequencing (scRNA-seq) to generate a comprehensive transcriptomic atlas from 25 EGFR mutant NSCLC samples. To assess immune microenvironment changes over time, time-series scRNA-seq and multiplex immunofluorescence analyses were performed in two DM patients. In vitro, EGFR-mutant cell lines were constructed to assess potential therapeutic responses for future clinical applications.

RESULTS

The scRNA-seq platform scFocuSCOPE accurately identified and characterized rare, mutation-bearing cancer cells at the single-cell level. DM cancer cells exhibited a strong tendency toward angiogenesis, suggesting an invasive phenotype. DM patients had a more suppressed immune microenvironment, with fewer dysfunctional T lymphocytes. The observation of fewer immune cells and high programmed death ligand-1 (PD-L1) expression in DM cases, probably related to immune evasion and poorer prognosis. In one DM patient, PD-L1 expression remained unchanged after targeted therapy but decreased after immunotherapy. In vitro, EGFR/ERBB2 DM cells showed greater sensitivity to dual-targeted therapies than to single-agent treatments.

CONCLUSIONS

scFocuSCOPE precisely delineated tumor heterogeneity and immune suppression in EGFR-DM NSCLC. The complex immune landscape of EGFR-DM tumors offers valuable insights for future mechanistic studies and personalized therapies.

Для цитирования: Yang Jiao, Su Jun-Wei, Li Hong-Rui, Fang Mei-Mei, Guan Xu-Hui, Lin Xiao-Cheng, Liu Ke-Jun, Yan Li-Xu, Zhang Xu-Chao, Yang Xue-Ning, Zhong Wen-Zhao, Chen Hua-Jun, Liu Jia, Wu Wendy, Yang Jin-Ji. Single-cell RNA profiling reveals an immunosuppressive microenvironment in EGFR double-mutant non-small cell lung cancer.. Translational lung cancer research. 2025. DOI: 10.21037/tlcr-2025-708.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.